drug · small molecule
ziftomenib
Marketedupdated 5mo agoby $KURA Kura Oncology, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Phase 1 2 (across all indications), with 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying ziftomenib
- phase3Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- phase2First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- phase2TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- phase1Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- phase1A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- phase2Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
- phase1A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- phase1A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 13, 2030
~4.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jul 16, 2044compositionUS 12410184
- Jul 16, 2044formulationUS 12521396
- Sep 6, 2038method-of-use (U-4349)US 11944627
- Mar 15, 2037compositionUS 10781218
- Mar 15, 2037method-of-use (U-4351)US 11673898
- Jan 26, 2037method-of-use (U-4353)US 10869868
- Mar 16, 2036compositionUS 10077271
- Mar 16, 2036method-of-use (U-4354)US 10174041
FDA exclusivities (1)
- Nov 13, 2030NCENew Chemical Entity (5y)4.1y
News(3)
- Kura spins diabetes work into a Lilly-backed biotech startupCaspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.biopharma_dive · 24d ago
- Kura Oncology spins out diabetes pipeline with $50M and Lilly's helpKura Oncology, the maker of the menin inhibitor Komzifti, is spinning out its diabetes R&D to a new company that has attracted the attention of the leading pharma in the metabolic field. ...endpoints · 24d ago
- Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyKura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment.fiercebiotech · 24d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that